The Immune, Inflammatory and Hematological Response in COVID-19 Patients, According to the Severity of the Disease

Introduction: The aim of this study was to evaluate the immune and inflammatory responses in COVID-19 patients by dosing specific IgM and IgG total antibodies and interleukin 6, correlating them with the hematological and biochemical blood parameters and comparing them by the form of the disease. Materials and methods: One hundred twenty-five patients with polymerase chain reaction-confirmed COVID-19, hospitalized between 15.03.2020 and 1.07.2020 in the Clinical Hospital of Infectious Diseases “Sf. Parascheva” Iaşi, were tested by chemiluminescence for the presence of anti-SARS-CoV-2 IgM and IgG and IL-6 in the serum. The results were correlated with the results of the CBC count and serum biochemical parameters detected on the admission day. The patients presented different forms of the disease (asymptomatic, mild, moderate, severe, and critical) according to World Health Organization (WHO) criteria for the clinical management of COVID-19. Results: The amplitude of the immune response was directly correlated with the form of the disease. In the asymptomatic/mild form patients, the IL-6 and CRP concentrations were significantly higher and eosinophil count was significantly lower compared with the reference interval. In the moderate form, the concentrations of IL-6, CRP, and IgG were significantly higher, compared with the reference interval, while eosinophil count and eGFR were significantly lower. In severe/critical COVID-19 patients, IL-6, CRP, NLR, PLR, glucose, AST, urea, creatinine, and eGFR were significantly higher compared with the reference interval, while eosinophil count was significantly lower. IL-6 boosted in all forms of COVID-19, with a major increase in severe and critical patients. IL-6, neutrophil count, % neutrophils, NLR, PLR, CRP, AST, and urea increased with the severity of the SARS-CoV-2 infection, and the lymphocyte count, % lymphocytes, eosinophil count, % eosinophils, and hemoglobin decreased with the increased severity of COVID-19. Conclusions: The amplitude and the moment of appearance of the immune response depended on the form of the disease. IgM generally occurred in the first 14 days of illness, and IgG appeared beginning with the second week of disease. IgG titer increased rapidly until the fourth week of disease and decreased slowly after 4 weeks. The amplitudes of all the tested inflammatory and serological markers depended on the COVID-19 form, increasing somewhat in the moderate forms and even more in the critical ones. The lymphocyte and eosinophil count are able to predict the risk of severe COVID-19.

[1]  D. Talwar,et al.  Association of serum ferritin with COVID-19 in a cross-sectional study of 200 intensive care unit patients in a rural hospital: Is ferritin the forgotten biomarker of mortality in severe COVID-19? , 2022, Journal of family medicine and primary care.

[2]  D. Talwar,et al.  Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital:A Cross-sectional Study , 2021, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[3]  Y. Shoenfeld,et al.  Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form , 2021, Pathogens.

[4]  Yongxiang Yi,et al.  Neutrophils and Lymphocytes Can Help Distinguish Asymptomatic COVID-19 From Moderate COVID-19 , 2021, Frontiers in Cellular and Infection Microbiology.

[5]  Philip R. O. Payne,et al.  Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19 , 2021, Research square.

[6]  Weijia Xie,et al.  Early kidney injury predicts disease progression in patients with COVID-19: a cohort study , 2021, BMC Infectious Diseases.

[7]  C. Bondor,et al.  Neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients , 2021, PloS one.

[8]  H. Bøtker,et al.  COVID-19 related cardiac complications - from clinical evidences to basic mechanisms. Opinion paper of the ESC Working Group on Cellular Biology of the Heart. , 2021, Cardiovascular research.

[9]  F. J. Carod-Artal,et al.  [Post-COVID-19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved]. , 2021, Revista de neurologia.

[10]  H. Yassine,et al.  Molecular and Biological Mechanisms Underlying Gender Differences in COVID-19 Severity and Mortality , 2021, Frontiers in Immunology.

[11]  K. Bhaskaran,et al.  Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform , 2021, The Lancet.

[12]  L. Anastácio,et al.  Risk factors for critical illness and death among adult Brazilians with COVID-19 , 2021, Revista da Sociedade Brasileira de Medicina Tropical.

[13]  M. Ouimet,et al.  Editorial: Covid-19 Mechanisms on Cardio-Vascular Dysfunction: From Membrane Receptors to Immune Response , 2021, Frontiers in Cardiovascular Medicine.

[14]  R. Müller,et al.  Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease , 2021, Infection.

[15]  K. Khunti,et al.  Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England , 2021, The Lancet Diabetes & Endocrinology.

[16]  D. Freedman,et al.  Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[17]  A. Spottke,et al.  Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort , 2021, Movement disorders : official journal of the Movement Disorder Society.

[18]  A. Gasbarrini,et al.  Predictors of in-hospital mortality AND death RISK STRATIFICATION among COVID-19 PATIENTS aged ≥ 80 YEARs OLD , 2021, Archives of Gerontology and Geriatrics.

[19]  K. Telle,et al.  Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study , 2021, Scandinavian journal of public health.

[20]  W. Lu,et al.  Identification of parameters in routine blood and coagulation tests related to the severity of COVID-19 , 2021, International journal of medical sciences.

[21]  Ling Zheng,et al.  Renal dysfunction and prognosis of COVID-19 patients: a hospital-based retrospective cohort study , 2020, BMC Infectious Diseases.

[22]  E. Devriendt,et al.  Risk factors for severe COVID-19 disease and death in patients aged 70 and over: a retrospective observational cohort study , 2020, Acta clinica Belgica.

[23]  J. Hodosy,et al.  Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak , 2020, BMC Infectious Diseases.

[24]  S. Hannawi,et al.  D-dimer, Troponin, and Urea Level at Presentation With COVID-19 can Predict ICU Admission: A Single Centered Study , 2020, Frontiers in Medicine.

[25]  Pei Wang Significance of IgA antibody testing for early detection of SARS‐CoV‐2 , 2020, Journal of medical virology.

[26]  T. Greenhalgh,et al.  Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services , 2020, BMC Health Services Research.

[27]  H. Peckham,et al.  Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission , 2020, Nature Communications.

[28]  B. O. Manin,et al.  A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level , 2020, Frontiers in Public Health.

[29]  U. Merle,et al.  COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry , 2020, Annals of Hematology.

[30]  L. Grohskopf,et al.  Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons , 2020, Clinical Infectious Diseases.

[31]  H. J. Kim,et al.  Effect of asthma and asthma medication on the prognosis of patients with COVID-19 , 2020, European Respiratory Journal.

[32]  E. Miller,et al.  Risk factors for severe acute respiratory syndrome coronavirus 2 infection in pregnant women , 2020, American Journal of Obstetrics & Gynecology Mfm.

[33]  S. Pancani,et al.  Closing the serological gap in the diagnostic testing for COVID‐19: The value of anti‐SARS‐CoV‐2 IgA antibodies , 2020, Journal of medical virology.

[34]  Sheng Hu,et al.  Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study , 2020, Journal of Translational Medicine.

[35]  M. Antonelli,et al.  Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. , 2020, JAMA internal medicine.

[36]  A. Sanyaolu,et al.  Comorbidity and its Impact on Patients with COVID-19 , 2020, SN Comprehensive Clinical Medicine.

[37]  Xi Zhou,et al.  Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients , 2020, Signal Transduction and Targeted Therapy.

[38]  Yajuan Li,et al.  Serum IgA, IgM, and IgG responses in COVID-19 , 2020, Cellular & Molecular Immunology.

[39]  B. Lipworth,et al.  Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[40]  H. Hakonarson,et al.  Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients , 2020, European Respiratory Journal.

[41]  H. Hou,et al.  Using IL‐2R/lymphocytes for predicting the clinical progression of patients with COVID‐19 , 2020, Clinical and experimental immunology.

[42]  E. Theel,et al.  The Role of Antibody Testing for SARS-CoV-2: Is There One? , 2020, Journal of Clinical Microbiology.

[43]  Florian Thiery,et al.  Linked COVID-19 Data: Johns Hopkins University (JHU) and European Centre for Disease Prevention and Control (ECDC) , 2020 .

[44]  T. Velavan,et al.  Mild versus severe COVID-19: Laboratory markers , 2020, International Journal of Infectious Diseases.

[45]  Qi Jin,et al.  Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  Xiuyong Li,et al.  Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19 , 2020, Journal of medical virology.

[47]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[48]  Tian Huang,et al.  COVID‐19 patients' clinical characteristics, discharge rate, and fatality rate of meta‐analysis , 2020, Journal of medical virology.

[49]  R. Lu,et al.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens. , 2020, JAMA.

[50]  Li Zhang,et al.  Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.

[51]  L Rampal,et al.  Coronavirus disease (COVID-19) pandemic. , 2020, The Medical journal of Malaysia.

[52]  C. Akdis,et al.  Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China , 2020, Allergy.

[53]  L. Chen,et al.  [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[54]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[55]  Xiao-Neng Mo,et al.  Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients , 2020, Emerging microbes & infections.